IPP Bureau
Twenty eight companies commit to Rs 6000 crore at Global Ayush meet
By IPP Bureau - April 23, 2022
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment
By IPP Bureau - April 23, 2022
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
CHMP adopts positive opinion on Tabrecta for advanced non-small cell lung cancer
By IPP Bureau - April 23, 2022
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Novavax initiates Covid-19 booster study in adolescents in Phase 3 trial
By IPP Bureau - April 23, 2022
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Covid-19 vaccine protection against hospitalization wanes
By IPP Bureau - April 23, 2022
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
IOL Chemicals and Pharmaceuticals commences commercial production of paracetamol
By IPP Bureau - April 23, 2022
All the capex is being met through internal accruals only
Brinton Pharmaceuticals to invest GBP 30 million for R&D centre in UK
By IPP Bureau - April 23, 2022
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
WHO recommends Paxlovid for Covid-19 therapy
By IPP Bureau - April 22, 2022
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
USFDA approves Phase 3 Acute Respiratory Distress Syndrome (ARDS), trial
By IPP Bureau - April 22, 2022
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Ayush Master Chef winners announced
By IPP Bureau - April 22, 2022
Within a fortnight, over 200 contestants sent their entries for the competition, and 30 names were shortlisted after screening entries under different categories
Terran Biosciences announces licensing deal with Sanofi
By IPP Bureau - April 22, 2022
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Thermo Fisher Scientific’s Clinical Research Business named `Best CRO’ at Vaccine Excellence awards
By IPP Bureau - April 22, 2022
The business is a recognized leader in managing Covid-19 and mRNA research programs
First ever nationwide epidemiological diabetes study released
By IPP Bureau - April 22, 2022
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
Qvella FAST System and FAST-PBC get CE marked and USFDA listed
By IPP Bureau - April 22, 2022
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Aurobindo Pharma signs MoU with Hare Krishna Charitable Foundation
By IPP Bureau - April 22, 2022
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
